AptaBio Therapeutics Inc.
KOE: 293780.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Jin Lee Soo
- Employees
- 32
- Headquarters
- Yongin-si, South Korea
- IPO year
- 2019
- Market cap
- ₩215.1B
- Website
- http://www.aptabio.com
Loading 293780…
Loading profile data…Frequently asked questions about 293780
What does AptaBio Therapeutics Inc. (293780.KQ) do?
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating...
Where does 293780.KQ trade?
AptaBio Therapeutics Inc. (293780.KQ) trades on the KOSDAQ.
What sector is 293780.KQ in?
AptaBio Therapeutics Inc. (293780.KQ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of AptaBio Therapeutics Inc.?
Jin Lee Soo is the chief executive officer of AptaBio Therapeutics Inc. (293780.KQ).
Where is AptaBio Therapeutics Inc. headquartered?
AptaBio Therapeutics Inc. is headquartered in South Korea.
Does 293780.KQ pay a dividend?
AptaBio Therapeutics Inc. (293780.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 293780.KQ go public?
AptaBio Therapeutics Inc. (293780.KQ) completed its initial public offering in 2019.